Fragile X therapy tackles underlying mechanism

28th August 2015

Fragile X therapy tackles underlying mechanismPhil Taylor

A potential therapy for rare disease Fragile X syndrome – one of the leading genetic causes of autism – is on its way to testing in clinical trials thanks to... Read more

Pharma gets social: Ten tweet chats transforming pharma digital engage…

27th August 2015

Pharma gets social: Ten tweet chats transforming pharma digital engagementDaniel Ghinn

Daniel Ghinn highlights why tweet chats are increasingly popular in the healthcare space.The past few years have seen healthcare companies take to Twitter increasingly to host and participate in public... Read more

How do you sell innovation to the NHS?

26th August 2015

How do you sell innovation to the NHS?Andrew McConaghie

Andrew McConaghie looks at how one region of England is helping to bridge the gap between life sciences innovation and the NHS.If you are a start-up company in the field... Read more

The power of the #hashtag

25th August 2015

The power of the #hashtagLeanne Orchard

This new series examines five ways in which social media is having an impact on the pharmaceutical and medical device industries, focusing on how it can be harnessed to help... Read more


Value model sets low price for Lilly's necitumumab

28th August 2015

Value model sets low price for Lilly's necitumumabPhil Taylor

With many new cancer drugs now costing $100,000 a year or more, US researchers have developed a model that works out a price range firmly based on their clinical value.The... Read more

World’s biggest cardiology congress comes to London

28th August 2015

World’s biggest cardiology congress comes to LondonAndrew McConaghie

The world's biggest cardiology congress kicks off in London on Saturday, with academics, heart specialists and pharma companies unveiling the latest insights into one of the world's biggest killers.The European... Read more

Novo Nordisk splashes out as oral semaglutide starts phase III

27th August 2015

Novo Nordisk splashes out as oral semaglutide starts phase IIIPhil Taylor

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials.If it reaches the market, the oral formulation... Read more

NICE says 'yes' to new anticoagulant Lixiana

26th August 2015

NICE says 'yes' to new anticoagulant LixianaPhil Taylor

Daiichi Sankyo's new anticoagulant Lixiana should be available on the NHS in England and Wales for the treatment and prevention of recurrent blood clots in the legs and lungs, according... Read more

Audio & Video

Live webinar: Accelerate the success of…

Zephyr data strategy webinar-new



Join this webinar to hear case studies and key success factors in using real world data and... View more

Available on demand: Changing behaviour:…

BrightTALK holding slide 4 22June


Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information... View more

Available on demand: Effectively using r…



Life sciences companies need to make better use of the insights that real-world data (RWD) can provide in order to improve market... View more

Available on demand: Exclusive debate/we…



The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

White Papers

Successful biopharma product launches de…

Successful biopharma product launches depend upon market insights – driving competitive advantage through innovationChristian Marcazzo & Robin Munro

A major competitive advantage can be gained by companies that unlock the value hidden in the vast quantity of healthcare data available today – particularly that presented by real-world data.View info

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Further News & Articles

Lilly and BI launch insulin biosimilar in the UK

A new cheaper biosimilar version of Sanofi's Lantus (insulin glargine) has been launched in the UK today, and is... Read more


Fallout from China's Black Monday limited - for now

China's stock market crash seems to have had only a short-lived impact on stock markets in Europe, with the NMX4... Read more


We’re getting closer to universal flu vaccine, say Janssen and Scripps

Further progress towards the development of a 'universal vaccine' to treat all strains of influenza has been ... Read more


Sean Bohen to head drug development at AstraZeneca

AstraZeneca (AZ) has poached Sean Bohen from Genentech to take the lead role in late stage development of its... Read more


Patient recommendations to enhance dementia trial engagement

As a patient advocate and someone with early-onset Alzheimer's disease, Michael Ellenbogen presents his ideas for im... Read more


Novartis takes complete control of GSK's Arzerra

In a $1 billion deal, GlaxoSmithKline (GSK) has transferred the remaining rights to its Arzerra product to Novar... Read more